|
1
|
Brown ZJ, Tsilimigras DI, Ruff SM, Mohseni
A, Kamel IR, Cloyd JM and Pawlik TM: Management of hepatocellular
carcinoma: A review. JAMA Surg. 158:410–420. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Sung H, Ferlay J, Siegel RL, Laversanne M,
Soerjomataram I, Jemal A and Bray F: Global cancer statistics 2020:
GLOBOCAN estimates of incidence and mortality worldwide for 36
cancers in 185 countries. CA Cancer J Clin. 71:209–249. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Peng Z, Fan W, Zhu B, Wang G, Sun J, Xiao
C, Huang F, Tang R, Cheng Y, Huang Z, et al: Lenvatinib combined
with transarterial chemoembolization as First-line treatment for
advanced hepatocellular carcinoma: A phase III, randomized clinical
trial (LAUNCH). J Clin Oncol. 41:117–127. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Yang C, Zhang H, Zhang L, Zhu AX, Bernards
R, Qin W and Wang C: Evolving therapeutic landscape of advanced
hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol.
20:203–222. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Siegel RL, Miller KD, Fuchs HE and Jemal
A: Cancer statistics, 2022. CA Cancer J Clin. 72:7–33. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ajoolabady A, Tang D, Kroemer G and Ren J:
Ferroptosis in hepatocellular carcinoma: Mechanisms and targeted
therapy. Br J Cancer. 128:190–205. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Zhan X, Wu R, Kong XH, You Y, He K, Sun
XY, Huang Y, Chen WX and Duan L: Elevated neutrophil extracellular
traps by HBV-mediated S100A9-TLR4/RAGE-ROS cascade facilitate the
growth and metastasis of hepatocellular carcinoma. Cancer Commun
(Lond). 43:225–245. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Shen C, Jiang X, Li M and Luo Y: Hepatitis
virus and hepatocellular carcinoma: Recent advances. Cancers
(Basel). 15:5332023. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Costante F, Stella L, Santopaolo F,
Gasbarrini A, Pompili M, Asselah T and Ponziani FR: molecular and
clinical features of hepatocellular carcinoma in patients with
HBV-HDV Infection. J Hepatocell Carcinoma. 10:713–724. 2023.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Zhou Q, Li L, Sha F, Lei Y, Tian X, Chen
L, Chen Y, Liu H and Guo Y: PTTG1 reprograms asparagine metabolism
to promote hepatocellular carcinoma progression. Cancer Res.
83:2372–2386. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Wang Z, Li N, Cai P, Zhang C, Cao G and
Yin J: Mechanism of HBx carcinogenesis interaction with non-coding
RNA in hepatocellular carcinoma. Front Oncol. 13:12491982023.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Li Y, Gan L, Lu M, Zhang X, Tong X, Qi D,
Zhao Y and Ye X: HBx downregulated decorin and decorin-derived
peptides inhibit the proliferation and tumorigenicity of
hepatocellular carcinoma cells. FASEB J. 37:e228712023. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Wu X, Ni Z, Song T, Lv W, Chen Y, Huang D,
Xie Y, Huang W and Niu Y: C-Terminal truncated HBx facilitates
oncogenesis by modulating cell cycle and glucose metabolism in
FXR-deficient hepatocellular carcinoma. Int J Mol Sci. 24:51742023.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
You H, Zhang N, Yu T, Ma L, Li Q, Wang X,
Yuan D, Kong D, Liu X, Hu W, et al: Hepatitis B virus X protein
promotes MAN1B1 expression by enhancing stability of GRP78 via
TRIM25 to facilitate hepatocarcinogenesis. Br J Cancer.
128:992–1004. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Dobrinić P, Szczurek AT and Klose RJ: PRC1
drives Polycomb-mediated gene repression by controlling
transcription initiation and burst frequency. Nat Struct Mol Biol.
28:811–824. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Zhu P, Cui N, Song ZY, Yong WX, Luo XX,
Wang GC, Wang X, Wu YN, Xu Q, Zhang LM, et al: PRC1 plays an
important role in lung adenocarcinoma and is potentially targeted
by fostamatinib. Eur Rev Med Pharmacol Sci. 26:8924–8934.
2022.PubMed/NCBI
|
|
17
|
Bu H, Li Y, Jin C, Yu H, Wang X, Chen J,
Wang Y, Ma Y, Zhang Y and Kong B: Overexpression of PRC1 indicates
a poor prognosis in ovarian cancer. Int J Oncol. 56:685–696.
2020.PubMed/NCBI
|
|
18
|
Huang R, Liu J, Li H, Zheng L, Jin H,
Zhang Y, Ma W, Su J, Wang M and Yang K: Identification of hub genes
and their correlation with immune infiltration cells in
hepatocellular carcinoma based on GEO and TCGA databases. Front
Genet. 12:6473532021. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Luo HW, Chen QB, Wan YP, Chen GX, Zhuo YJ,
Cai ZD, Luo Z, Han ZD, Liang YX and Zhong WD: Protein regulator of
cytokinesis 1 overexpression predicts biochemical recurrence in men
with prostate cancer. Biomed Pharmacother. 78:116–120. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Li M, Xiao Y, Liu P, Wei L, Zhang T, Xiang
Z, Liu X, Zhang K, Zhong Q and Chen F: 4–Methoxydalbergione
inhibits esophageal carcinoma cell proliferation and migration by
inactivating NF–κB. Oncol Rep. 49:422023. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Liu Y, Liu X, Luo M, Li Y and Li H: HBx
modulates drug resistance of Sorafenib-resistant hepatocellular
carcinoma cells. Discov Med. 35:1035–1042. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Yu J, Li W, Hou GJ, Sun DP, Yang Y, Yuan
SX, Dai ZH, Yin HZ, Sun SH, Huang G, et al: Circular RNA cFAM210A,
degradable by HBx, inhibits HCC tumorigenesis by suppressing YBX1
transactivation. Exp Mol Med. 55:2390–2401. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
He L, Shen H, Deng H, Zhang X, Xu Y, Shi C
and Ouyang Z: Identification of critical residues in the regulatory
protein HBx for Smc5/6 interaction and hepatitis B virus
production. Antiviral Res. 211:1055192023. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Lei Y, Xu X, Liu H, Chen L, Zhou H, Jiang
J, Yang Y and Wu B: HBx induces hepatocellular carcinogenesis
through ARRB1-mediated autophagy to drive the G1/S cycle.
Autophagy. 17:4423–4441. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Peantum J, Kunanopparat A, Hirankarn N,
Tangkijvanich P and Kimkong I: Autophagy Related-protein 16-1
Up-regulated in hepatitis B Virus-related hepatocellular carcinoma
and impaired apoptosis. Gastroenterology Res. 11:404–410. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Lin X, Li AM, Li YH, Luo RC, Zou YJ, Liu
YY, Liu C, Xie YY, Zuo S, Liu Z, et al: Silencing MYH9 blocks
HBx-induced GSK3β ubiquitination and degradation to inhibit tumor
stemness in hepatocellular carcinoma. Signal Transduct Target Ther.
5:132020. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Kimkong I and Kunanopparat A: Autophagy
related protein 9A increase in hepatitis B virus-associated
hepatocellular carcinoma and the role in apoptosis. World J
Hepatol. 12:1367–1371. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Debnath J, Gammoh N and Ryan KM: Autophagy
and autophagy-related pathways in cancer. Nat Rev Mol Cell Bio.
24:560–575l. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Gong K, Chen C, Zhan Y, Chen Y, Huang Z
and Li W: Autophagy-related gene 7 (ATG7) and reactive oxygen
species/extracellular signal-regulated kinase regulate
tetrandrine-induced autophagy in human hepatocellular carcinoma. J
Biol Chem. 287:35576–35588. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Sun H, Yu J, Wen Z, Wang M and Chen W:
Decreased expression of Beclin-1 in patients with hepatocellular
carcinoma. J BUON. 24:634–641. 2019.PubMed/NCBI
|
|
32
|
Qian ZM, Chen YJ and Bao YX:
Pharmacological mechanisms of norcantharidin against hepatocellular
carcinoma. Am J Cancer Res. 13:5024–5038. 2023.PubMed/NCBI
|
|
33
|
Vargas JNS, Hamasaki M, Kawabata T, Youle
RJ and Yoshimori T: The mechanisms and roles of selective autophagy
in mammals. Nat Rev Mol Cell Biol. 24:167–185. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Yu JL and Gao X: MicroRNA 1301 inhibits
cisplatin resistance in human ovarian cancer cells by regulating
EMT and autophagy. Eur Rev Med Pharmacol Sci. 24:1688–1696.
2020.PubMed/NCBI
|
|
35
|
Kudo Y, Sugimoto M, Arias E, Kasashima H,
Cordes T, Linares JF, Duran A, Nakanishi Y, Nakanishi N, L'Hermitte
A, et al: PKCλ/ι loss induces autophagy, oxidative phosphorylation,
and NRF2 to promote liver cancer progression. Cancer Cell.
38:247–262. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Perchey RT, Serres MP, Nowosad A, Creff J,
Callot C, Gay A, Manenti S, Margolis RL, Hatzoglou A and Besson A:
p27Kip1 regulates the microtubule bundling activity of PRC1.
Biochim Biophys Acta Mol Cell Res. 1865:1630–1639. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Huang J, Zhan Y, Jiang L, Gao Y, Zhao B,
Zhang Y, Zhang W, Zheng J and Yu J: Identification of the potential
prognosis biomarkers in hepatocellular carcinoma: An analysis based
on WGCNA and PPI. Int J Gen Med. 14:9555–9565. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Shi J, Hao S, Liu X, Li Y and Zheng X:
Feiyiliu Mixture sensitizes EGFRDel19/T790M/C797S mutant non-small
cell lung cancer to osimertinib by attenuating the PRC1/Wnt/EGFR
pathway. Front Pharmacol. 14:10930172023. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Chen W, Chen M, Zhao Z, Weng Q, Song J,
Fang S, Wu X, Wang H, Zhang D, Yang W, et al: ZFP36 binds with PRC1
to inhibit tumor growth and increase 5-Fu chemosensitivity of
hepatocellular carcinoma. Front Mol Biosci. 7:1262020. View Article : Google Scholar : PubMed/NCBI
|
